Board of Directors

Anne C. Whitaker


Anne Whitaker is a seasoned healthcare executive and director with more than 30 years of extensive leadership and commercialization experience in pharmaceuticals, biotech, consumer products, and medical devices. She currently serves as managing partner of Anne Whitaker Group, LLC, a life science board and private equity advisory firm. She has held senior-level executive leadership roles at Sanofi, GlaxoSmithKline (GSK), Bausch Health, and multiple CEO roles for private and public development-stage companies.

Anne is currently the chair of Aerami Therapeutics, where she was the company’s CEO from 2018-2020. Anne serves as an independent director of  Orasure Technologies  (NASDAQ: OSUR), Faron Pharmaceuticals (AIM: FARN), Caladrius Biosciences (NASDAQ: CLBS), ErgoMed Plc (LSE:ERGO), Nykode Therapeutics ASA, Curio Digital Therapeutics, Trinity Life Science Partners and Bryn Pharmaceuticals.

Anne has been recognized in the pharmaceutical industry by Fierce Pharma as one of the top 25 Most Influential People in BioPharma in 2012 and 2013, and in 2014 as one of the top 25 Most Influential Women in BioPharma. She was recognized in 2020 by PharmaVoice as one of the Top 100 most Inspiring Leaders in Healthcare and by Women, Inc. as one of the most Influential Corporate Directors in 2019. She is a member of Women Corporate Directors, International Women’s Forum and OnBoardNC. She holds a B.S. in chemistry from the University of North Alabama.